What is Cytosorbents Corp.'s earnings per share (EPS)?

Cytosorbents Corp. (CTSO) reported diluted earnings per share of -$0.13 for fiscal year 2025. This represents a 65.8% change compared to the previous fiscal year. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Cytosorbents Corp. (CTSO) Financials

CTSO

Trailing 12 months to June 30, 2026

Revenue $37.2M +3.1% YoY

Net Income -$18.2M -84.5% YoY

EPS (Diluted) -$0.29 -61.1% YoY

Free Cash Flow -$9.3M +7.4% YoY

Market Cap $13.0M as of Oct 17, 2026

Price / Sales 0.3x on $37.2M revenue, trailing 12 months to June 30, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026

Price / Book n/m negative shareholder equity, so no book multiple, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 17, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 6, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 6, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the CTSO SEC filings page.

Cytosorbents Corp. (CTSO) reported $37.2M in revenue over the twelve months to Jun 30, 2026, up 3.1% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 15 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI CTSO FY2025 2026-10-04

Cytosorbents is improving its losses, but still funds a cash-consuming operation increasingly through financing.

FY2025 paired a 71.5% gross margin with a -39.8% operating margin, showing that product-level economics are considerably stronger than the full cost structure. The small gap between operating cash flow of -$12.4M and free cash flow of -$12.5M indicates that reinvestment is not the main cash drain; ongoing operations are.

Revenue reached $37.1M in FY2025, while gross margin expanded to 71.5% from 69.9%. With operating loss narrowing to $14.7M, the improvement reflects more than volume alone: costs are consuming less of each sales dollar.

Debt-to-equity rose to 2.8x from 1.3x as equity fell to $5.9M, making the financing structure more leveraged. Reported liquidity equaled 6.1 months of the latest annual operating outflow, while free cash flow remained negative.

Financial Health Signals

Financial Health Score 37/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group; the overall is their average, with missing dimensions counted as zero out of six. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Cytosorbents Corp.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Cytosorbents Corp. held $6.2M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $12.4M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Cytosorbents Corp. scores 21/100 among other emerging companies.

Dilution

Cytosorbents Corp. had 63M shares outstanding at the end of fiscal year 2025, against 63M in fiscal year 2024. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Cytosorbents Corp. scores 53/100 among other emerging companies.

R&D Intensity

Not available for Cytosorbents Corp., and counted as zero in the overall score.

Revenue Progress

Cytosorbents Corp. reported revenue of $37.1M in fiscal year 2025, against $35.6M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Cytosorbents Corp. scores 54/100 among other emerging companies.

Burn Trend

Cytosorbents Corp.'s operations used $12.4M of cash in fiscal year 2025, against $14.4M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Cytosorbents Corp. scores 68/100 among other emerging companies.

Balance Sheet

Cytosorbents Corp.'s cash, cash equivalents and investments came to $6.2M at the end of fiscal year 2025, against $38.3M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Cytosorbents Corp. scores 23/100 among other emerging companies.

Altman Z-Score Distress

-9.66

Cytosorbents Corp. scores -9.66, below the 1.81 distress threshold. The score is driven primarily by a large market capitalization ($13.0M) relative to total liabilities ($38.3M). This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Weak

3/9

Cytosorbents Corp. passes 3 of 9 financial strength tests. 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality No Cash Backing

N/A

Cytosorbents Corp. reported a net loss of $8.2M while operations used $12.4M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Interest Coverage At Risk

N/A

Cytosorbents Corp. reported an operating loss of $14.7M against $2.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$9.6M

YoY+0.2%

QoQ+8.7%

5Y CAGR-4.3%

10Y CAGR+15.8%

Cytosorbents Corp. generated $9.6M in revenue in Q2 2026. This represents an increase of 0.2% from the same quarter a year earlier. Against the prior quarter it is up 8.7%.

EBITDA

-$2.3M

YoY+30.0%

QoQ+15.4%

Cytosorbents Corp.'s EBITDA was -$2.3M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. This represents an increase of 30.0% from the same quarter a year earlier. Against the prior quarter it is up 15.4%.

Net Income

-$4.4M

YoY-326.9%

QoQ+13.9%

Cytosorbents Corp. reported -$4.4M in net income in Q2 2026. This represents a decrease of 326.9% from the same quarter a year earlier. Against the prior quarter it is up 13.9%.

EPS (Diluted)

-$0.07

YoY-333.3%

QoQ+12.5%

Cytosorbents Corp. earned -$0.07 per diluted share (EPS) in Q2 2026. This represents a decrease of 333.3% from the same quarter a year earlier. Against the prior quarter it is up 12.5%.

Cash & Balance Sheet

Free Cash Flow

-$597K

YoY+61.4%

QoQ+49.1%

Cytosorbents Corp. recorded an outflow of $597K in free cash flow in Q2 2026, representing a cash shortfall after capex. This represents an increase of 61.4% from the same quarter a year earlier. Against the prior quarter it is up 49.1%.

Cash & Debt

$4.4M

YoY-56.8%

QoQ-8.3%

5Y CAGR-41.7%

10Y CAGR-6.5%

Cytosorbents Corp. held $4.4M in cash against $3.1M in long-term debt as of Q2 2026.

Shares Outstanding

63M

YoY+0.1%

QoQ+0.1%

5Y CAGR+7.7%

10Y CAGR+9.5%

Cytosorbents Corp. had 63M shares outstanding in Q2 2026. This represents an increase of 0.1% from the same quarter a year earlier. Against the prior quarter it is up 0.1%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

73.2%

YoY+2.3pp

QoQ+4.0pp

5Y change-4.3pp

10Y change+12.5pp

Cytosorbents Corp.'s gross margin was 73.2% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 2.3 percentage points from the same quarter a year earlier. Against the prior quarter it is up 4.0 percentage points.

Operating Margin

-27.4%

YoY+10.2pp

QoQ+7.0pp

5Y change+13.6pp

Cytosorbents Corp.'s operating margin was -27.4% in Q2 2026, reflecting core business profitability. This is up 10.2 percentage points from the same quarter a year earlier. Against the prior quarter it is up 7.0 percentage points.

Net Margin

-45.9%

YoY-66.1pp

QoQ+12.0pp

5Y change-7.0pp

Cytosorbents Corp.'s net profit margin was -45.9% in Q2 2026, showing the share of revenue converted to profit. This is down 66.1 percentage points from the same quarter a year earlier. Against the prior quarter it is up 12.0 percentage points.

Return on Equity

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$1.5M

YoY+15.1%

QoQ+41.8%

Cytosorbents Corp. invested $1.5M in research and development in Q2 2026. This represents an increase of 15.1% from the same quarter a year earlier. Against the prior quarter it is up 41.8%.

Capital Expenditures

$14K

YoY-62.2%

QoQ+27.3%

5Y CAGR-55.3%

10Y CAGR-13.9%

Cytosorbents Corp. invested $14K in capex in Q2 2026, funding long-term assets and infrastructure. This represents a decrease of 62.2% from the same quarter a year earlier. Against the prior quarter it is up 27.3%.

Share Buybacks

Not reported for Q2 2026.

CTSO Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CTSO quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Revenue	$37.2M	$37.1M+4.1%	$35.6M+14.5%	$31.1M-10.4%	$34.7M-19.6%	$43.2M+5.3%	$41.0M+64.4%	$24.9M+10.9%	$22.5M+48.5%	$15.2M+59.0%	$9.5M+98.8%	$4.8M+16.2%	$4.1M+70.2%	$2.4M+80.4%	$1.3M+3622.3%	$36K
Cost of Revenue	$10.6M	$10.6M-1.3%	$10.7M+17.3%	$9.1M-34.6%	$14.0M+26.3%	$11.0M0.0%	$11.1M+50.1%	$7.4M-1.7%	$7.5M+35.7%	$5.5M+39.6%	$4.0M+78.7%	$2.2M+3.7%	$2.1M+11.6%	$1.9M+498.7%	$319K+2615.1%	$12K
Gross Profit	$26.6M	$26.5M+6.4%	$24.9M+13.4%	$22.0M+5.9%	$20.7M-35.4%	$32.1M+7.2%	$30.0M+70.3%	$17.6M+17.1%	$15.0M+55.9%	$9.6M+72.8%	$5.6M+116.1%	$2.6M+29.7%	$2.0M+289.1%	$511K-50.1%	$1.0M+4109.4%	$24K
R&D Expenses	N/A	N/A	N/A	$15.7M+4.0%	$15.1M-7.7%	$16.4M+85.9%	$8.8M-27.1%	$12.1M+56.6%	$7.7M+139.8%	$3.2M-20.9%	$4.1M+5.2%	$3.9M+59.2%	$2.4M+39.8%	$1.7M-31.3%	$2.5M-12.3%	$2.9M
SG&A Expenses	$34.2M	$35.6M+5.7%	$33.7M-11.9%	$38.3M+11.7%	$34.3M-4.1%	$35.8M+25.6%	$28.5M+29.3%	$22.0M+5.4%	$20.9M+40.0%	$14.9M+26.3%	$11.8M+70.6%	$6.9M+24.7%	$5.6M+115.5%	$2.6M+90.2%	$1.4M+10.1%	$1.2M
Operating Income	-$12.9M	-$14.7M+10.4%	-$16.5M+48.5%	-$31.9M-1.4%	-$31.5M-38.6%	-$22.7M-119.3%	-$10.4M+45.3%	-$19.0M-21.7%	-$15.6M-58.3%	-$9.8M+14.4%	-$11.5M-23.5%	-$9.3M-35.0%	-$6.9M-46.2%	-$4.7M-35.0%	-$3.5M+21.3%	-$4.4M
EBITDA	N/A	-$13.5M+10.6%	-$15.1M+50.4%	-$30.5M+0.5%	-$30.6M-39.2%	-$22.0M-126.7%	-$9.7M+47.2%	-$18.4M-21.0%	-$15.2M-57.9%	-$9.6M+15.1%	-$11.3M-23.3%	-$9.2M-34.6%	-$6.8M-46.9%	-$4.6M-35.3%	-$3.4M+21.9%	-$4.4M
Interest Expense	$3.1M	$2.6M+86.7%	$1.4M+786.1%	$158K	N/A	N/A	$1.2M+16.2%	$1.0M-29.3%	$1.5M+95.0%	$749K+223.2%	$232K	$0-100.0%	$199K-36.0%	$311K+31.9%	$236K-54.3%	$516K
Income Tax	-$401K	-$401K+76.3%	-$1.7M-107.8%	-$814K+25.5%	-$1.1M-48.4%	-$736K+34.7%	-$1.1M-3.2%	-$1.1M-76.3%	-$620K+8.5%	-$677K-112.4%	-$319K+1.9%	-$325K+15.8%	-$386K+15.8%	-$458K-17.0%	-$392K	N/A
Net Income	-$18.2M	-$8.2M+60.4%	-$20.7M+29.2%	-$29.2M+10.9%	-$32.8M-33.6%	-$24.6M-213.4%	-$7.8M+59.3%	-$19.3M-11.9%	-$17.2M-103.4%	-$8.5M+28.1%	-$11.8M-24.1%	-$9.5M-1.7%	-$9.3M-99.3%	-$4.7M-27.7%	-$3.7M+33.2%	-$5.5M
EPS (Basic)	N/A	-$0.13+65.8%	-$0.38+41.5%	-$0.65+13.3%	-$0.75-31.6%	-$0.57-185.0%	-$0.20+66.7%	-$0.60	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	-$0.29	-$0.13+65.8%	-$0.38+41.5%	-$0.65+13.3%	-$0.75-31.6%	-$0.57-185.0%	-$0.20+66.7%	-$0.60	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Diluted Shares (Avg)	N/A	62M+14.3%	54M+21.9%	45M+2.5%	44M+0.5%	43M+11.7%	39M+20.3%	32M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$9.6M+0.2%	$8.9M+1.6%	$9.2M+0.9%	$9.5M+10.1%	$9.6M+8.8%	$8.7M-2.9%	$9.2M+5.6%	$8.6M-2.2%
Cost of Revenue	$2.6M-7.8%	$2.7M+8.5%	$2.4M-16.1%	$2.8M-16.0%	$2.8M+19.8%	$2.5M+19.1%	$2.9M	$3.4M+4.8%
Gross Profit	$7.0M+3.4%	$6.1M-1.2%	$6.8M+8.8%	$6.7M+26.8%	$6.8M+4.8%	$6.2M-9.7%	$6.3M+17.8%	$5.3M-6.3%
R&D Expenses	$1.5M+15.1%	$1.0M-38.4%	N/A	N/A	$1.3M-17.0%	$1.7M-26.0%	N/A	$1.9M-50.6%
SG&A Expenses	$8.0M-13.1%	$8.1M-3.4%	$9.4M+23.6%	$8.6M+4.2%	$9.2M+7.2%	$8.4M-9.2%	$7.6M	$8.3M+1.9%
Operating Income	-$2.6M+27.0%	-$3.0M+21.7%	-$4.4M-29.1%	-$2.9M+40.7%	-$3.6M-1.3%	-$3.9M+16.5%	-$3.4M+63.9%	-$4.8M+34.3%
EBITDA	-$2.3M+30.0%	-$2.7M+23.5%	-$4.2M-32.3%	-$2.6M+43.4%	-$3.3M-2.7%	-$3.5M+17.4%	-$3.2M+65.0%	-$4.5M+34.8%
Interest Expense	$868K+40.9%	$857K+41.7%	$746K+20.3%	$645K+9.7%	$616K+242.2%	$605K+5547.3%	$620K	$588K+1646.4%
Income Tax	$0	$0	$0	-$401K	$0	$0	N/A	$0
Net Income	-$4.4M-326.9%	-$5.1M-246.8%	-$5.5M+27.4%	-$3.2M-14.5%	$1.9M+145.3%	-$1.5M+75.7%	-$7.6M-29.7%	-$2.8M+69.9%
EPS (Basic)	-$0.07-333.3%	-$0.08-300.0%	-$0.09+35.7%	-$0.050.0%	$0.03+137.5%	-$0.02+81.8%	-$0.14-16.7%	-$0.05+76.2%
EPS (Diluted)	-$0.07-333.3%	-$0.08-300.0%	-$0.09+35.7%	-$0.050.0%	$0.03+137.5%	-$0.02+81.8%	-$0.14-16.7%	-$0.05+76.2%
Diluted Shares (Avg)	63M-6.5%	63M+3.3%	N/A	63M+15.2%	67M+23.7%	61M+11.6%	N/A	54M+22.7%

CTSO Balance Sheet

CTSO quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Total Assets	$44.2M-6.7%	$47.4M-10.5%	$53.0M-16.3%	$63.2M-29.4%	$89.5M-0.5%	$90.0M+228.5%	$27.4M-19.9%	$34.2M+41.9%	$24.1M+148.6%	$9.7M-13.9%	$11.3M+32.9%	$8.5M+109.3%	$4.0M+21.2%	$3.3M+57.3%	$2.1M
Current Assets	$20.6M-4.5%	$21.6M-14.9%	$25.4M-24.8%	$33.8M-47.5%	$64.3M-22.0%	$82.5M+294.5%	$20.9M-26.0%	$28.3M+36.3%	$20.7M+164.9%	$7.8M-20.6%	$9.9M+29.6%	$7.6M+118.2%	$3.5M+18.6%	$2.9M+73.2%	$1.7M
Cash & Equivalents	$6.2M+90.5%	$3.3M-76.8%	$14.1M-36.2%	$22.1M-57.5%	$52.1M-27.0%	$71.4M+483.9%	$12.2M-45.3%	$22.4M+29.1%	$17.3M+230.2%	$5.2M-1.3%	$5.3M+47.5%	$3.6M+65.2%	$2.2M+26.2%	$1.7M+45.7%	$1.2M
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0-100.0%	$2.2M+12.7%	$1.9M	$0	$0	$0
Inventory	$5.3M+93.2%	$2.7M-19.0%	$3.4M-2.5%	$3.5M-27.4%	$4.8M+78.3%	$2.7M+26.5%	$2.1M+153.7%	$833K+4.7%	$796K-4.6%	$834K-30.0%	$1.2M+121.5%	$538K+118.9%	$246K-64.0%	$682K+58.3%	$431K
Accounts Receivable	$7.5M+3.1%	$7.3M+20.9%	$6.1M+6.9%	$5.7M+25.2%	$4.5M-12.3%	$5.2M+15.5%	$4.5M+13.3%	$3.9M+78.8%	$2.2M+53.9%	$1.4M+120.9%	$649K-20.8%	$819K+80.8%	$453K+774.9%	$52K+43.5%	$36K
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$38.3M+5.6%	$36.3M+23.0%	$29.5M+5.8%	$27.9M+3.4%	$26.9M+151.0%	$10.7M-55.2%	$24.0M+38.8%	$17.3M+24.7%	$13.8M+65.6%	$8.4M+174.5%	$3.0M+99.7%	$1.5M-91.7%	$18.3M+22.4%	$15.0M+22.5%	$12.2M
Current Liabilities	$9.7M-1.2%	$9.8M-30.0%	$14.0M+44.5%	$9.7M-29.0%	$13.7M+34.8%	$10.2M+2.2%	$9.9M+43.7%	$6.9M-11.9%	$7.8M+83.5%	$4.3M+40.6%	$3.0M	N/A	$3.1M+47.6%	$2.1M+35.9%	$1.5M
Non-Current Liabilities	$28.6M+8.1%	$26.4M+71.2%	$15.4M-14.9%	$18.1M+36.9%	$13.3M+2178.2%	$582K-95.9%	$14.0M+35.6%	$10.3M+72.6%	$6.0M+46.9%	$4.1M	$0	N/A	$15.2M+18.3%	$12.9M+4565.3%	$276K
Long-Term Debt	$16.7M+19.1%	$14.0M+450.4%	$2.5M-49.1%	$5.0M	N/A	$0-100.0%	$13.4M+44.3%	$9.3M+54.8%	$6.0M+46.9%	$4.1M	$0	N/A	N/A	N/A	N/A
Total Equity	$5.9M-46.9%	$11.1M-52.7%	$23.5M-33.6%	$35.4M-43.5%	$62.6M-21.0%	$79.2M+2217.6%	$3.4M-79.8%	$16.9M+65.0%	$10.3M+667.3%	$1.3M-86.4%	$9.8M+41.8%	$6.9M+148.7%	-$14.3M-22.7%	-$11.6M-15.2%	-$10.1M
Retained Earnings	-$312.2M-2.7%	-$304.0M-7.3%	-$283.3M-11.5%	-$254.0M-14.8%	-$221.2M-12.5%	-$196.6M-4.2%	-$188.8M-11.4%	-$169.5M-11.3%	-$152.3M-6.1%	-$143.5M-8.3%	-$132.5M-6.5%	-$124.4M-17.6%	-$105.8M	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$38.0M-20.9%	$40.6M-20.1%	$44.2M-6.7%	$45.8M-4.3%	$48.0M-10.2%	$50.8M+7.9%	$47.4M-10.5%	$47.8M+0.5%
Current Assets	$15.7M-31.5%	$17.8M-30.1%	$20.6M-4.5%	$21.3M+28.4%	$23.0M+4.7%	$25.4M+27.1%	$21.6M-14.9%	$16.6M-13.8%
Cash & Equivalents	$4.4M-56.8%	$4.8M-58.5%	$6.2M+90.5%	$7.5M+32.6%	$10.2M+20.6%	$11.6M+34.6%	$3.3M-76.8%	$5.7M-32.0%
Short-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Inventory	$3.7M-0.6%	$4.5M+48.5%	$5.3M+93.2%	$4.0M+23.2%	$3.7M-14.1%	$3.0M-19.3%	$2.7M-19.0%	$3.2M+9.1%
Accounts Receivable	$6.8M-12.4%	$7.2M-6.8%	$7.5M+3.1%	$7.4M+12.0%	$7.7M-1.0%	$7.7M+13.4%	$7.3M+20.9%	$6.6M+7.3%
Long-Term Investments	$0	$0	$0	$0	$0	$0	$0	$0
Total Liabilities	$38.7M+6.3%	$38.4M+5.9%	$38.3M+5.6%	$36.7M+6.0%	$36.4M+1.1%	$36.2M+32.1%	$36.3M+23.0%	$34.7M+20.5%
Current Liabilities	$24.0M+144.1%	$16.3M+67.4%	$9.7M-1.2%	$10.1M+22.1%	$9.8M+2.1%	$9.7M-23.5%	$9.8M-30.0%	$8.3M-29.0%
Non-Current Liabilities	$14.7M-44.7%	$22.1M-16.7%	$28.6M+8.1%	$26.6M+0.9%	$26.6M+0.8%	$26.5M+80.1%	$26.4M+71.2%	$26.4M+54.3%
Long-Term Debt	$3.1M-78.5%	$10.3M-27.3%	$16.7M+19.1%	$14.6M+5.5%	$14.4M+5.1%	$14.2M+635.6%	$14.0M+450.4%	$13.8M+228.8%
Total Equity	-$751K-106.5%	$2.2M-84.9%	$5.9M-46.9%	$9.0M-32.6%	$11.6M-33.5%	$14.5M-25.9%	$11.1M-52.7%	$13.4M-28.9%
Retained Earnings	-$321.8M-6.0%	-$317.3M-3.9%	-$312.2M-2.7%	-$306.7M-3.5%	-$303.5M-3.4%	-$305.5M-5.6%	-$304.0M-7.3%	-$296.4M-7.0%

Not reported in any period shown, so not listed: Goodwill.

CTSO Cash Flow Statement

CTSO quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Operating Cash Flow	-$9.1M	-$12.4M+14.2%	-$14.4M+33.4%	-$21.7M+23.3%	-$28.2M-101.6%	-$14.0M-149.5%	-$5.6M+66.5%	-$16.8M-54.6%	-$10.8M-67.8%	-$6.5M+4.0%	-$6.7M+25.6%	-$9.0M-35.8%	-$6.7M-90.9%	-$3.5M+3.5%	-$3.6M+5.5%	-$3.8M
Depreciation & Amortization	N/A	$1.2M-7.6%	$1.3M-8.5%	$1.5M+65.3%	$883K+20.6%	$732K+10.7%	$661K+13.6%	$582K+48.9%	$391K+78.9%	$218K+35.1%	$162K+43.1%	$113K+72.3%	$66K+1.9%	$64K+17.8%	$55K+39.5%	$39K
Stock-Based Compensation	N/A	$2.8M-26.5%	$3.8M-9.5%	$4.2M+21.4%	$3.4M-14.9%	$4.0M+14.4%	$3.5M+110.9%	$1.7M-62.5%	$4.4M+33.9%	$3.3M+20.2%	$2.8M+621.1%	$382K-45.1%	$696K+52.3%	$457K+624.1%	$63K-92.7%	$866K
Capital Expenditures	$150K	$164K-42.3%	$284K-47.2%	$538K-91.2%	$6.1M+67.2%	$3.6M+414.0%	$708K+1.5%	$698K+3.9%	$672K-32.2%	$991K+604.0%	$141K-65.1%	$404K+163.5%	$153K+295.9%	$39K+94.9%	$20K-42.7%	$35K
Free Cash Flow	-$9.3M	-$12.5M+14.8%	-$14.7M+33.7%	-$22.2M+35.3%	-$34.3M-94.5%	-$17.6M-179.1%	-$6.3M+63.8%	-$17.5M-51.6%	-$11.5M-54.5%	-$7.5M-8.4%	-$6.9M+27.3%	-$9.5M-38.7%	-$6.8M-93.2%	-$3.5M+3.0%	-$3.6M+5.9%	-$3.9M
Investing Cash Flow	-$275K	-$415K+38.0%	-$669K+28.5%	-$936K+85.5%	-$6.5M-50.8%	-$4.3M-155.4%	-$1.7M-10.3%	-$1.5M0.0%	-$1.5M+9.4%	-$1.7M-205.1%	$1.6M+279.2%	-$891K+61.5%	-$2.3M-968.5%	-$216K-457.5%	-$39K+26.1%	-$52K
Financing Cash Flow	N/A	$9.3M-0.2%	$9.3M-35.5%	$14.5M+191.8%	$5.0M+593.5%	$715K-98.9%	$66.3M+711.3%	$8.2M-53.2%	$17.5M-13.2%	$20.1M+297.4%	$5.1M-56.5%	$11.6M+16.2%	$10.0M+138.3%	$4.2M-0.2%	$4.2M+5.0%	$4.0M

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$583K+61.4%	-$1.2M+66.5%	-$4.8M-106.1%	-$2.6M-4.6%	-$1.5M+68.5%	-$3.5M+28.2%	-$2.3M+63.5%	-$2.5M+52.7%
Depreciation & Amortization	$360K0.0%	$350K-5.0%	$97K-37.0%	$300K0.0%	$360K-10.2%	$369K-7.2%	$154K-60.6%	$300K-26.3%
Stock-Based Compensation	$368K-35.6%	$544K-33.5%	N/A	$488K-45.2%	$571K-42.3%	$818K-14.7%	N/A	$891K-18.0%
Capital Expenditures	$14K-62.2%	$11K+450.0%	$108K+56.5%	$17K-88.8%	$37K+107.8%	$2K-95.6%	$69K-27.7%	$152K+6.7%
Free Cash Flow	-$597K+61.4%	-$1.2M+66.2%	-$4.9M-104.7%	-$2.6M+0.8%	-$1.5M+67.9%	-$3.5M+28.9%	-$2.4M+62.9%	-$2.6M+51.1%
Investing Cash Flow	$7K+105.3%	-$46K+2.1%	-$291K-134.7%	$55K+118.4%	-$132K-10.9%	-$47K+63.0%	-$124K+8.8%	-$299K-16.0%
Financing Cash Flow	N/A	N/A	$2.5M+1383.8%	$0+100.0%	$0-100.0%	$6.8M+1294.7%	$167K-98.6%	-$99K-115.3%

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

CTSO Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

CTSO quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K	FY1310-K	FY1210-K	FY1110-K
Gross Margin	71.5%+1.6pp	69.9%-0.7pp	70.6%+10.9pp	59.8%-14.6pp	74.4%+1.4pp	73.0%+2.6pp	70.5%+3.8pp	66.7%+3.1pp	63.6%+5.1pp	58.5%+4.7pp	53.8%+5.6pp	48.2%+27.1pp	21.1%-55.1pp	76.2%+8.8pp	67.4%
Operating Margin	-39.8%+6.4pp	-46.2%	-102.8%	-90.9%-38.2pp	-52.7%-27.4pp	-25.3%+50.8pp	-76.0%-6.8pp	-69.3%-4.3pp	-65.0%	-120.6%	-194.2%	-167.2%	-194.6%	-259.9%	-12297.7%
Net Margin	-22.1%+36.1pp	-58.2%+35.9pp	-94.1%+0.5pp	-94.6%-37.7pp	-56.9%-37.8pp	-19.1%+58.1pp	-77.2%-0.7pp	-76.5%-20.6pp	-55.8%	-123.5%	-197.8%	-226.1%	-193.1%	-272.8%	-15193.9%
Return on Equity	-138.9%+47.7pp	-186.5%-62.0pp	-124.6%-31.8pp	-92.8%-53.5pp	-39.2%-29.4pp	-9.9%+553.8pp	-563.6%-462.0pp	-101.6%-19.2pp	-82.4%+797.1pp	-879.5%-783.3pp	-96.3%+38.0pp	-134.2%	N/A	N/A	N/A
Return on Assets	-18.6%+25.2pp	-43.7%+11.5pp	-55.2%-3.3pp	-51.9%-24.5pp	-27.4%-18.7pp	-8.7%+61.7pp	-70.4%-20.0pp	-50.3%-15.2pp	-35.1%+86.3pp	-121.4%-37.1pp	-84.2%+25.9pp	-110.1%+5.5pp	-115.6%-5.9pp	-109.7%+148.5pp	-258.3%
Current Ratio	2.13-0.1x	2.20+0.4x	1.81-1.7x	3.48-1.2x	4.70-3.4x	8.12+6.0x	2.10-2.0x	4.09+1.4x	2.64+0.8x	1.83-1.4x	3.24	N/A	1.14-0.3x	1.42+0.3x	1.11
Debt-to-Equity	2.82+1.6x	1.26+1.2x	0.110.0x	0.14-0.3x	0.43+0.4x	0.00-3.9x	3.92+3.4x	0.550.0x	0.58-2.5x	3.05+3.0x	0.00-0.2x	0.22	N/A	N/A	N/A
Asset Turnover	0.84+0.1x	0.75+0.2x	0.590.0x	0.55+0.1x	0.480.0x	0.46-0.5x	0.91+0.3x	0.660.0x	0.63-0.4x	0.98+0.6x	0.43-0.1x	0.49-0.1x	0.60+0.2x	0.40+0.4x	0.02
FCF Margin	-33.8%+7.5pp	-41.3%+30.1pp	-71.4%+27.5pp	-98.9%-58.1pp	-40.9%-25.5pp	-15.4%+54.5pp	-70.0%-18.8pp	-51.1%-2.0pp	-49.2%+22.9pp	-72.1%	-197.3%	-165.3%	-145.6%	-270.8%	-10707.9%

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-Q	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	73.2%+2.3pp	69.2%-2.0pp	73.7%+5.3pp	70.3%+9.3pp	70.9%-2.7pp	71.1%-5.3pp	68.3%+7.1pp	61.0%-2.6pp
Operating Margin	-27.4%+10.2pp	-34.3%+10.2pp	-47.5%-10.4pp	-30.2%+25.9pp	-37.6%+2.8pp	-44.5%+7.3pp	-37.1%	-56.1%+27.3pp
Net Margin	-45.9%-66.1pp	-57.9%-40.9pp	-59.5%+23.2pp	-33.4%-1.3pp	20.3%+68.8pp	-17.0%+50.8pp	-82.7%-15.4pp	-32.1%
Return on Equity	N/A	-233.8%-223.6pp	-93.1%-25.0pp	-35.1%-14.5pp	16.8%+41.4pp	-10.2%+20.8pp	-68.1%-43.3pp	-20.7%+28.2pp
Return on Assets	-11.6%-15.7pp	-12.6%-9.7pp	-12.4%+3.5pp	-6.9%-1.1pp	4.1%+12.1pp	-2.9%+10.0pp	-16.0%-5.0pp	-5.8%+13.5pp
Current Ratio	0.66-1.7x	1.09-1.5x	2.13-0.1x	2.11+0.1x	2.34+0.1x	2.61+1.0x	2.20+0.4x	2.00+0.4x
Debt-to-Equity	N/A	4.70+3.7x	2.82+1.6x	1.61+0.6x	1.24+0.5x	0.98+0.9x	1.26+1.2x	1.03+0.8x
Asset Turnover	0.25+0.1x	0.220.0x	0.210.0x	0.210.0x	0.200.0x	0.170.0x	0.190.0x	0.180.0x
FCF Margin	-6.2%+9.9pp	-13.2%+26.5pp	-53.4%-27.1pp	-27.4%+3.0pp	-16.1%+38.3pp	-39.7%+14.5pp	-26.3%+48.7pp	-30.4%+30.3pp

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Cytosorbents Corp. CTSO	FY2025	$37.1M	-$8.2M	-22.1%	$13.0M	37/100
WORK Medical Technology Group LTD WOK	FY2025	$9.8M	-$1.1M	-10.9%	$4.9M	22/100
Elutia Inc. ELUT	FY2025	$12.3M	$53.4M	N/A	$35.2M	26/100
TELA Bio, Inc. TELA	FY2025	$80.3M	-$38.8M	-48.3%	$44.0M	46/100
Sensus Healthcare, Inc SRTS	FY2025	$27.5M	-$7.7M	-28.1%	$45.6M	48/100
Spectral AI, Inc. MDAI	FY2025	$19.6M	-$7.6M	-38.5%	$48.6M	37/100

Where Cytosorbents Corp. Ranks

Frequently Asked Questions

What is Cytosorbents Corp.'s annual revenue?

Cytosorbents Corp. (CTSO) reported $37.1M in total revenue for fiscal year 2025. This represents a 4.1% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Cytosorbents Corp.'s revenue growing?

Cytosorbents Corp. (CTSO) revenue grew by 4.1% year-over-year, from $35.6M to $37.1M in fiscal year 2025.

Is Cytosorbents Corp. profitable?

No, Cytosorbents Corp. (CTSO) reported a net income of -$8.2M in fiscal year 2025, with a net profit margin of -22.1%.

What is Cytosorbents Corp.'s EBITDA?

Cytosorbents Corp. (CTSO) had EBITDA of -$13.5M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

How much debt does Cytosorbents Corp. have?

As of fiscal year 2025, Cytosorbents Corp. (CTSO) had $6.2M in cash and equivalents against $16.7M in long-term debt.

What is Cytosorbents Corp.'s gross margin?

Cytosorbents Corp. (CTSO) had a gross margin of 71.5% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Cytosorbents Corp.'s operating margin?

Cytosorbents Corp. (CTSO) had an operating margin of -39.8% in fiscal year 2025, reflecting the profitability of core business operations before interest and taxes.

What is Cytosorbents Corp.'s net profit margin?

Cytosorbents Corp. (CTSO) had a net profit margin of -22.1% in fiscal year 2025, representing the share of revenue converted into profit after all expenses.

What is Cytosorbents Corp.'s return on equity (ROE)?

Cytosorbents Corp. (CTSO) has a return on equity of -138.9% for fiscal year 2025, measuring how efficiently the company generates profit from shareholder equity.

What is Cytosorbents Corp.'s free cash flow?

Cytosorbents Corp. (CTSO) recorded an outflow of $12.5M in free cash flow during fiscal year 2025. This represents a 14.8% change compared to the previous fiscal year. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Cytosorbents Corp.'s operating cash flow?

Cytosorbents Corp. (CTSO) recorded an outflow of $12.4M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Cytosorbents Corp.'s total assets?

Cytosorbents Corp. (CTSO) had $44.2M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Cytosorbents Corp.'s capital expenditures?

Cytosorbents Corp. (CTSO) invested $164K in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How many shares does Cytosorbents Corp. have outstanding?

Cytosorbents Corp. (CTSO) had 63M shares outstanding as of fiscal year 2025.

What is Cytosorbents Corp.'s current ratio?

Cytosorbents Corp. (CTSO) had a current ratio of 2.13 as of fiscal year 2025, which is generally considered healthy.

What is Cytosorbents Corp.'s debt-to-equity ratio?

Cytosorbents Corp. (CTSO) had a debt-to-equity ratio of 2.82 as of fiscal year 2025, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Cytosorbents Corp.'s return on assets (ROA)?

Cytosorbents Corp. (CTSO) had a return on assets of -18.6% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Cytosorbents Corp.'s P/E ratio?

Cytosorbents Corp. (CTSO) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $13.0M as of Oct 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Cytosorbents Corp.'s price-to-sales ratio?

Cytosorbents Corp. (CTSO) trades at 0.3x sales, its market capitalization divided by revenue of $37.2M revenue, trailing 12 months to June 30, 2026. The market capitalization is $13.0M as of Oct 17, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Cytosorbents Corp.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Cytosorbents Corp. (CTSO) held $6.2M in cash, cash equivalents and investments, and reported an operating cash outflow of $12.4M over that year. Dividing the one by the other, the reported balance equals about 6 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

What is Cytosorbents Corp.'s Altman Z-Score?

Cytosorbents Corp. (CTSO) has an Altman Z-Score of -9.66, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Cytosorbents Corp.'s Piotroski F-Score?

Cytosorbents Corp. (CTSO) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Cytosorbents Corp.'s earnings high quality?

Cytosorbents Corp. (CTSO) reported a net loss of $8.2M while operations used $12.4M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

Can Cytosorbents Corp. cover its interest payments?

Cytosorbents Corp. (CTSO) reported an operating loss of $14.7M against $2.6M in interest expense. There is no operating profit to cover interest, so interest must be met from cash reserves or from financing rather than from operations. This ratio divides operating income by interest expense. Ratios above 5x indicate strong debt-servicing ability, while ratios below 2x suggest the company may face difficulty meeting interest payments if earnings decline. Learn more in our complete guide to financial health indicators.

How financially healthy is Cytosorbents Corp.?

Cytosorbents Corp. (CTSO) scores 37 out of 100 on our Financial Health Score, indicating weak standing within its emerging companies peer group. The score is a 0-100 composite of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.